- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02892487
Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer (RORC)
Toxicity and mainly dysphagia have increased in head and neck cancers as chemoradiation indications have risen over the last decade, leading to a significant loss of quality of life for patients. Recently, many retrospective studies and two evidence-based and systematic reviews on strategies to reduce radiation-induced dysphagia have suggested a trend toward benefit for a preventive swallowing exercise program.
The main hypothesis of this study is that an early active swallowing therapy can improve the Quality of Life (QoL) of patients treated by radiotherapy for head and neck cancer.
The study will be a randomized controlled, open-label, multicentric phase III clinical trial comparing early active swallowing therapy versus non specific swallowing management (usual care).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients in both groups will receive dietary and postural advice from the treating physician. Patients in the experimental group will be treated with an early active swallowing therapy including a consultation with a speech and language therapist twice a week and a detailed program of swallowing auto-exercises twice a day, from the start to one month after the end of radiotherapy. All speech therapists will be given precise guidelines based on the current state of the art and knowledge. All patients will be analyzed in intent-to-treat.
Two ancillary studies will complete this global concept of the evaluation and prediction of severe alteration of Quality of Life (QoL) and Dysphagia.
- A first study will evaluate videoradioscopy. Its objectives are to evaluate the ability of videoradioscopy at 3 months to predict poor QoL at 6 and 12 months, to identify videoradioscopic predictors of severe dysphagia, asymptomatic aspirations, cricopharyngeal stenoses and active swallowing rehabilitation efficiency. Each patient of both arms of the main study will undergo a videoradioscopy before the beginning of the radiation delivery (baseline evaluation), and at 3 and at 12 months. Data analysis will be centralized and will concern: APS (Aspiration and Penetration Scale) score, residue, Defective Laryngeal elevation, pharyngoesophageal sphincter dysfunction. Data will be correlated to the parameters of the main study in order to establish predictive models.
- A second ancillary study will evaluate the dose-volume histograms of radiotherapy. The objectives are to identify predictors of dysphagia and of active swallowing rehabilitation efficiency, and to establish "2D" and "3D" predictive models of dysphagia. Imaging and dosimetric data (IMRT (Intensity Modified RadioTherapy) planning) and dose-volume histogram will be collected from the patients of the main clinical trial. Analysis will be centralized. Data will be correlated to the parameters of the main study in order to establish predictive models.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brest, France
- Brest University Hospital
-
Caen, France
- Centre Francois Baclesse
-
Caen, France
- Caen University Hospital
-
Clermont-Ferrand, France
- Clermont-Ferrand University Hospital
-
Le Mans, France
- Le Mans Hospital
-
Lille, France
- Lille University Hospital
-
Lorient, France
- Bretagne Sud Hospital
-
Lyon, France
- Lyon University Hospital
-
Marseille, France
- Marseille University hospital
-
Nancy, France
- Centre Alexis Vautrin
-
Nantes, France
- Nantes University Hospital
-
Nice, France
- Centre Antoine Lacassagne
-
Paris, France
- Tenon Hospital
-
Poitiers, France
- Poitiers University Hospital
-
Rennes, France
- Rennes University Hospital
-
Rennes, France
- Clinique La sagesse
-
Strasbourg, France
- Strasbourg University Hospital
-
Toulouse, France
- Toulouse University Hospital
-
Tours, France
- Tours University Hospital
-
Vannes, France
- Bretagne Atlantique Hospital
-
Villejuif, France
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient treated for histologically proven head and neck cancer (oral cavity, oropharynx, or hypopharynx cancer) of stages I-IV or larynx cancer of stages II-IV, all histologic type, without distant metastasis
- Indication of curative radiotherapy alone or associated to chemotherapy or targeted therapy, without planned surgery
- WHO (World Health Organization) Performance Status 0, 1 or 2
- Sufficient cognitive capacities to complete a QoL questionnaire (evaluation by the physician at inclusion)
- Written informed consent
- Patients with health insurance
Exclusion Criteria:
- Previous radiotherapy or surgery of the upper aerodigestive tract
- Cancer of paranasal sinuses or nasopharynx or skull base
- Medical history of nervous system disease associated to significant sequelae in terms of dysphagia
- Pregnant or breast-feeding woman
- Patient under guardianship, trusteeship or judicial protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual care
|
|
|
Experimental: Early active swallowing therapy
|
Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients experiencing a clinically relevant improvement defined as a decrease of at least 10 points of the score HNSW ( 6 months after radiotherapy compared with the score before radiotherapy
Time Frame: 6 months after radiotherapy
|
HNSW = Head and Neck Swallowing Questionnaire
|
6 months after radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EORTC QLQ-C30 score
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
EORTC QLQ = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
EORTC H&N35 score
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
EORTC H&N = European Organisation for Research and Treatment of Cancer Head and Neck questionnaire
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
MFI-20 score
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
MFI = Multidimensional Fatigue Inventory
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
Body Mass index (BMI)
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
in kg/m^2
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
Functional Oral Intake Scale (FOIS)
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
|
Overall duration of enteral nutrition
Time Frame: 12 months after radiotherapy
|
12 months after radiotherapy
|
|
|
Total treatment duration
Time Frame: 12 months after radiotherapy
|
12 months after radiotherapy
|
|
|
Number of treatment interruptions
Time Frame: 12 months after radiotherapy
|
12 months after radiotherapy
|
|
|
Number of patients with adverse events
Time Frame: End of radiotherapy (an average of 2 months after baseline), 1, 3, 6 and 12 months after radiotherapy
|
End of radiotherapy (an average of 2 months after baseline), 1, 3, 6 and 12 months after radiotherapy
|
|
|
Swallowing specific Quality of Life (SWAL-QOL) score
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
|
Number of patients with aspiration and penetration determined by APS (Aspiration and Penetration Scale) scoring
Time Frame: Baseline, 3, 6 and 12 months after radiotherapy
|
Baseline, 3, 6 and 12 months after radiotherapy
|
|
|
Rate of global survival
Time Frame: 12 months after radiotherapy
|
12 months after radiotherapy
|
|
|
Rate of survival without recurrence
Time Frame: 12 months after radiotherapy
|
12 months after radiotherapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Franck JEGOUX, Rennes University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35RC14_9786_RORC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of Head and Neck
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Bristol-Myers SquibbOno Pharma USA IncCompletedCancer of Head and Neck | Cancer of the Head | Cancer of the NeckJapan
-
AstraZenecaCompletedCancer of Head and NeckSpain
-
Washington University School of MedicineCelgene CorporationCompletedHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
University of Alabama at BirminghamAventis PharmaceuticalsCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neck NeoplasmsUnited States
-
Bristol-Myers SquibbCompletedSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineTerminatedHead and Neck Cancer | Cancer of the Head and NeckUnited States
-
Royal Marsden NHS Foundation TrustRecruitingHead and Neck CancerUnited Kingdom
-
University of ChicagoCompletedHead and Neck CancerUnited States
Clinical Trials on Swallowing therapy
-
Qilu Hospital of Shandong UniversityRecruiting
-
University of FloridaNational Center for Medical Rehabilitation Research (NCMRR)CompletedDysphagiaUnited States
-
University of South FloridaNot yet recruiting
-
Chang Gung Memorial HospitalRecruiting
-
Chang Gung Memorial HospitalCompletedStroke | Dysphagia | Videofluoroscopy
-
Barretos Cancer HospitalCompletedSwallowing Disorders | Head Neck CancerBrazil
-
Irene WesselRigshospitalet, Denmark; Danish Cancer Society; Danish Association of Occupational... and other collaboratorsCompleted
-
University of California, San FranciscoNew York University; Emory UniversityCompletedCognitive Impairment | Cognitive Decline | Voice Disorders | Swallowing Disorder | Voicebox DisordersUnited States
-
IRCCS National Neurological Institute "C. Mondino...Fondazione Don Carlo Gnocchi Onlus; Istituti Clinici Scientifici Maugeri SpA; ASST Santi Paolo e Carlo and other collaboratorsCompleted
-
Chang Gung Memorial HospitalCompleted